Assessing therapeutically developed assays
- PMID: 19097282
Assessing therapeutically developed assays
Abstract
Risk classification of early-stage breast cancer patients by gene expression profiling can result in substantial drug cost savings. Economic analyses suggest that appropriate use of clinically validated molecular diagnostics offers the potential for cost savings and improved patient quality of life.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical